ArticleEuropean heart journal open2026
Reduced postprandial lipid accumulation in circulating monocytes by olezarsen attenuates pro-inflammatory changes in hypertriglyceridemic patients.
Article in European heart journal open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Postprandial Inflammatory Stress: A Hypothesis-Generating Framework Linking Metabolic, Immune and Vascular Responses.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Aims: The pathophysiological mechanisms linking hypertriglyceridaemia to atherosclerotic cardiovascular disease remain incompletely understood. Accumulating evidence implicates postprandial triglyceride-rich lipoproteins in lipid accumulation and activation of monocytes, thereby exacerbating arterial wall inflammation. Olezarsen lowers fasting and postprandial triglycerides, but its effect on monocyte activation in hypertriglyceridaemia remains unclear. Methods and results: In this double-blind, randomized, placebo-controlled trial, 28 patients with hypertriglyceridaemia (fasting triglycerides ≥350 mg/dL) received two 80 mg doses of subcutaneous olezarsen or placebo (2:1) at 4-weekly intervals. Peripheral blood mononuclear cells and CD14⁺ monocytes were isolated 4 h after a standardized oral fat load for phenotyping.Oral fat load induced a marked triglyceride increase, accompanied by a 49.0% [95% CI: 30.2%, 71.0%] ( Conclusion: Olezarsen reduced postprandial lipid droplet accumulation in monocytes and was associated with decreased expression of activation markers and reduced monocyte adhesion and transendothelial migration of monocytes
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.